Takeda Pharmaceutical Li...
13.05
0.06 (0.46%)
At close: Jan 14, 2025, 3:59 PM
13.04
-0.08%
After-hours Jan 14, 2025, 07:00 PM EST
undefined%
Bid 12.93
Market Cap 41.37B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.57
PE Ratio (ttm) 22.89
Forward PE n/a
Analyst Buy
Ask 14.14
Volume 1,552,155
Avg. Volume (20D) 1,712,426
Open 13.03
Previous Close 12.99
Day's Range 13.00 - 13.10
52-Week Range 12.58 - 15.08
Beta undefined

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Reves...

Sector Healthcare
IPO Date Jan 5, 2010
Employees 49,281
Stock Exchange NYSE
Ticker Symbol TAK

Analyst Forecast

According to 1 analyst ratings, the average rating for TAK stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Takeda Pharmaceutical Limited is scheduled to release its earnings on Jan 30, 2025, before market opens.
Analysts project revenue of $7.61M, reflecting a -99.9% YoY shrinking and earnings per share of 0.64, making a 25.49% increase YoY.
5 months ago · Source
+3.76%
Takeda shares are trading higher after the Europea... Unlock content with Pro Subscription
7 months ago · Source
-3.8%
Takeda Pharmaceutical shares are trading lower after the company announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial.